Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues (Q36307088)

13 August 2017

1 reference

title

Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues (English)

1 reference

13 August 2017

0 references

1 reference

1

Hans-Jürgen Möller

1 reference

13 August 2017

1 January 2005

1 reference

World Journal of Biological Psychiatry

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

4

1 reference

13 August 2017

247-263

1 reference

Depression in the long-term course of schizophrenia.

13 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Cognitive approach to depression and suicidal thinking in psychosis. 1. Ontogeny of post-psychotic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Psychological pathways to depression in schizophrenia: studies in acute psychosis, post psychotic depression and auditory hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Schizophrenia and affective disorders--cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

The AMDP-system in clinical psychopharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Reliability of the AMDP-system. A preliminary report on a multicentre exercise on the reliability of psychopathological assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Bupropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Zur Validierung der AMDP-Syndromskalen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Overview of psychiatric comorbidity. Practical and theoretic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

The early course of schizophrenia and depression*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Psychotic Episodes and Postpsychotic Depression in Young Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Pharmacotherapy of impaired affect in recovering schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Psychopathology and cognition in schizophrenia spectrum disorders: the role of depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

The significance of depression in the prediction of relapse in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Depression in schizophrenia: I. Association with neuropsychological deficits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Affective processes in the onset and persistence of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Lithium combined with haloperidol in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Schizoaffective disorder: clinical aspects, differential diagnosis, and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Postpsychotic depression in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Management of the negative symptoms of schizophrenia: new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Non-neuroleptic approaches to treating negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Antidepressant Usage in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Suicidal behavior in patients with schizophrenia and other psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Depression during the longitudinal course of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Efficiency of the AMDP anamnestic data in psychiatric research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Manic-depressive illness and good prognosis schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Schizophrenia: genes and environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

PROSPECTIVE PREDICTION OF SCHIZOPHRENIC REMISSION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970500316674

10.1080/15622970500316674

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16272080